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Abstract 
This is a study of the HIV cohort at the The Ullevål Department of Infectious Disease, Oslo 
University Hospital (IDU). We have studied the success of ART (anti retroviral therapy) on 
the HIV population in a historic perspective, examining success and failure rates from 1998 to 
2010. Furthermore we have looked at different demographic groups in the HIV population, 
trying to identify whether viral transmission group, age, ethnicity or gender is predictive of 
ART failure.  
I also studied various biological markers, both prior to treatment and current values. The aim 
was to identify whether biological markers exist that can predict later HIV failure, and to 
characterize treatment failure biologically. Looking at this information for different 
demographic groups, I found that different predictors exist for different transmission groups.  
This publishment is a draft of an article, planned published in the near future in a journal of 
infectious diseases. The article will be written with Professor Dag Kvale and dr Vidar 
Ormåsen as co-writers. All use of results, figures and text is prohibited untill June 2015, based 
on an agreement between the author and University of Oslo (see “Klausuleringsregler”). 
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1 Introduction 
The Ullevål Department of Infectious Disease, Oslo University Hospital (IDU) has been 
treated HIV patients since the 1980s, and is the number one center in Norway on HIV 
treatment. In the beginning, anti retroviral therapy (ART) was a tough treatment, with many 
and grave side effects and low success rates. The introduction of HAART in the late 1990s 
changed these success rates radically, and its continous development in the past decade has 
transformed HIV from being a lethal disease to be a chronic disease for the majority of the 
infected, also with more moderate side effects of the treatment. 
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2 Methods 
2.1 Selection criteria and characterization of 
patients 
The Ullevål Department of Infectious Disease, Oslo University Hospital (IDU) holds the 
largest HIV cohort in Norway with 768 patients on antiretroviral treatment (ART) by 31. 
December 2009. An approved clinical data base for quality evaluations contains data on all of 
the patients followed by the clinic in the HIV era.  
The criteria for inclusion were HIV seropositivity and clinical follow-up data for at least 2 
years.  Patients were evaluated for virological ART failure defined by HIV RNA > 400 
copies/mL on at the last visit prior to analysis, provided that the patients on ART for at least 6 
months.  
Various patients groups were examined in relation to ART failure including age, gender, 
nationality of birth, and risk groups. Nationality was defined as western (European, North 
America, and Oceania) or non–western (South America, Asia and Africa). The larger risk 
groups in relation to viral transmission were defined as heterosexual (hetero), men who have 
sex with men (msm), are men who were infected during homosexual activity, and injecting 
drug users.  
2.2 Statistical methods 
We used the statistical program Statistica, version 7.0 for all analyses (StatSoft, OK, USA). 
Non-parametric tests including the Mann–Whitney U-test were generally used to characterize 
the study population, whereas distribution differences were calculated by Chi square. 
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3 Results 
3.1 The decline in virological ART failure 1998-2010  
The prevalence of virological ART failure on 1 January 1998 became gradually reduced from 
61% to 9 % in 2010 (Fig. 1).  
 
Figure 1. Patients on ART between 1998 and 2010. Percentages and shaded areas represent patients with 
virological failure (HIV RNA > 400 copies/mL) after at least 6 months of ART. 
3.2 Predictors of treatment failure 
We started our study with looking at characteristics for the patients failing, to see if they 
differ in age, gender, risk group and nationality compared to the HIV population as a whole, 
but could not demonstrate any clear characteristics of the patients failing treatment (Fig. 2). 
Transmission risk groups seem be to similar to international figures. In our total population, 
heterosexual represent 45 percent, MSM 44% and injecting drug users 8 %, an international 
study shows 36, 40 and 16 respectively [1]. 
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Figure 2. Demography and transmission categories of current HIV patients (1 January 2010). Percentages and 
shaded areas represent patients with virological failure (HIV RNA > 400 copies/mL) after at least 6 months of 
ART. 
 
We also looked more in detail within these and other groups where one might could anticipate 
differences in ART efficacy, such as former AIDS diagnosis. To our surprise, we did not find 
any differences in the distribution of treatment failure patients, except a surprisingly better 
treatment result in patients > 60 years (p=0.04) and probably a higher rate of virological 
failure in injecting drug users (p=0.07) (Table 1). We also looked into females in general as 
well as in non-western females. Although both these groups had numerically higher failure 
rates, these were not statistically different (Table 1).  
  
0
100
200
300
400
0-30 31-40 41-50 51-60 61-90
Age
12%
n=205
7%
n=291
11%
n=36
3%
n=77
10%
n=159
0
100
200
300
400
500
600
700
western non-western
Nationality
7%
n=523
11%
n=229
0
100
200
300
400
500
600
700
male female
Gender
8%
n=554
11%
n=214
0
100
200
300
400
500
hetero msm drug users other
Risk group
8%
n=342
7%
n=335
15%
n=61
10%
n=30
9 
 
Table 1. Frequency of demographic groups with virological success and failure. 
    
Patient group 
Virological 
success 
Virological 
failure 
P* 
(%) (%) 
n=702 n=66 
Former AIDS diagnosis 24 20 0.56 
Age > 60 years 11 3 0.04 
Non-western 30 39 0.12 
MSM 46 39 0.53 
Injecting drug users 7 14 0.07 
Females 27 36 0.11 
Non-western females 15 23 0.14 
p* chi square, absolute numbers.     
 
 
We then examined some of available classical pre-ART parameters representing the immune 
constition such as CD4+ T cell counts, the virological control (HIV RNA, CD8+ count 
(Pettersen et al., 2010) as well as weak parameters for immune activation ( 2-microglobulin), 
but none of these variables were predictive for later virological ART failure for the cohort as a 
whole (Table 2). For some groups however, 2-microglobulin pre-treatment proved to be a 
possible predictor for later failure (Figure 3). Our interpretation of this is that HAART 
treatment has a positive effect on the immune defense system, without restoring the immune 
system fully in those seriously affected by HIV infection. 
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Table 2. Characteristics of current study population by December 2009.  
Median values with IQ range. 
  
  Current HIV RNA   
  < 400 > 400 P* 
  (n=702) (n=66)   
Pre treatment values     
CD4 190 (110-270) 180 (120-250) 0.76 
CD8 
975 (630-
1415)  860 (565-1280) 0.22 
CD4/CD8 ratio 
0.17 (0.11-
0.29)  0.19 (0.13-0.29) 0.30 
HIV RNA 
130' (40' – 
410') 110' (44'-430') 0.64 
2-microglobulin 2.9 (2.2-3.6) 3.0 (2.4-3.7) 0.70 
Age 37 (31-44) 34 (29-40) <0,01 
      
Current values (on treatment)     
CD4 522 (370-671) 355 (198-559) <0.01 
CD8 
1009 (753-
1368) 1183 (830-1695) 0.03 
CD4/CD8 ratio 
0.51 (0.34-
0.75) 0.30 (0.20-0.39) <0.01 
HIV RNA 2 (0-2) 
4800 (1000-
51000) <0.01 
2-microglobulin 1.9 (1.6-2.3) 2.7 (2.2-3-4) <0.01 
Hb 
14.3 (13.2-
15.2) 13.6 (12.1-14.6) <0.01 
Albumin 44 (42-46) 43 (40-45) <0.01 
Age 46 (39-53) 44 (37-51) 0.07 
      
Months of treatment 76 (35-139) 79 (37-139) 0.73 
Months of HIV diagnosis 114 (66-188) 125 (84-198) 0.11 
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Figure 3. Pre-treatment beta-2 microglobulin values for two demographic groups of HIV-patients on HAART, 
intra-venous drug users and patients with former AIDS history. Cathegorisation by current HIV-RNA values, 
values above 400 copies/mL defined as virological failure. Diamonds mark median values, lines mark the 25-
75% interval.  
We also examined the patients’ age at the time of treatment start, and to our surprise low age 
proved to be a significant predictive factor for later treatment failure, an opposite finding to 
what we would have postulated (Table 2). Further examination of the data showed that young 
age as a predictive factor for later treatment failure is mainly an issue for MSM, where 
median age pre treatment is 7 years younger among those failing treatment compared to those 
were treatment is successful. No such difference in age is to be seen in the other large 
demographic group, heterosexual women. MSM failing treatment also have a significantly 
higher CD4/CD8 ratio, which is also contradictory to what we would have postulated (Table 
3). 
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Table 3. Characteristics of current study population, heterosexual females cohort and MSM cohort, December 2009.  
Median values with IQ range. 
 
We then looked at the current data of the population. Looking at all patients failing treatment 
as a whole, keeping with a concurrent median viraemia at 4800 HIV RNA copies/mL, these 
patients are clearly affected by their treatment failure by having substantially lower CD4 
counts and higher immune activation in terms of 2-microglobulin. Levels of hemoglobin and 
albumin are also significantly lower. Their duration of treatment and length of HIV infection 
is similar to patients treated with success (Table 1). Heterosexual women failing treatment 
have a significantly longer time of HIV diagnosis that women treated with success, while time 
of treatment is similar (table 3). 
 
       
  Heterosexual females - current HIV RNA MSM - current HIV RNA 
  < 400 > 400 P* < 400 > 400 P* 
  (n=155) (n=21)   (n=310) (n=25)   
Pre treatment values         
CD4 190 (100-250) 146.5 (50-250) 0.29 180 (104-260) 190 (130-260) 0.52 
CD8 736 (520-1232) 735 (515-1020) 0.54 
1060 (701-
1460) 
1090 (510-
1390) 0.64 
CD4/CD8 ratio 
0.19 (0.11-
0.37) 0.20 (0.09-0.20) 0.41 
0.17 (0.098-
0.26) 
0.22 (0.14-
0.36) 0.046 
HIV RNA 79' (21'-220') 235' (39'-600') 0.045 155' (48' – 490') 205' (87'-530') 0.42 
2-microglobulin 2.4 (1.7-3.1) 2.85 (1.80-3.70) 0.31 3.0 (2.3-3.8) 2.9 (2.4-3.1) 0.52 
Age 30 (27-37) 32.5 (29-37) 0.39 40 (34-46) 33 (28-37) <0.01 
          
Current values (on 
treatment)         
CD4 517 (370-671) 323 (188-402) <0.01 545 (405 – 699) 
525 (351 – 
706) 0.45 
CD8 900 (653-1208) 1019 (746-1291) 0.33 
1069 (821 – 
1474) 
1365 (971-
2220) 0.03 
CD4/CD8 ratio 
0.56 (0.41 – 
0.84) 0.30 (0.21-0.37) <0.01 0.51 (0.34-0.73) 
0.33 (0.219-
0.55) <0.01 
HIV RNA 0 (0-2) 
6700 (1400-
51000) <0.01 2 (0-2) 
2000 (980-
20000) <0.01 
2-microglobulin 1.6 (1.3-2.0) 
2.65 (2.250-
3.65) <0.01 2.0 (1.7-2.3) 2.55 (2.0-3.15) <0.01 
Hb 12.7 (12-13.4) 11.6 (11.0-12.7) <0.01 14.9 (14.3-15.5) 
14.6 (14.1-
15.35) 0.47 
Albumin 43 (41-44) 40.5 (35-43) <0.01 45 (43-46) 45 (41-48) 0.82 
Age 39 (34-45) 40 (35-49) 0.37 48 (41-56) 42 (38-50) <0.01 
          
Months of treatment 70 (38-121) 77 (48-118) 0.61 76 (28-144) 85 (62-145) 0.22 
Months of HIV diagnosis 92 (63-149) 120 (89-153) 0.049 123 (66-201) 150 (90-183) 0.26 
* Mann Whitney analysis      
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MSM failing treatment seem to be less affected by their treatment failure, they have similar 
CD4 but significantly higher CD8 counts than MSM who experience successful treatment. 
They keep being significantly younger in age at time of failure than those treated successfully 
(table 3). 
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4 Discussion 
Our study has shown that the introduction of HAART in the late 1990s has had a great impact 
on the success rates in the treatment of HIV. Prevalence of virological failure has continously 
decreased from 61 percent in 1998 to 9 percent in 2010, leaving little doubt that HIV 
treatment is continously improving. An international study from 2006 shows similar findings 
[1]. 
Stratifications show little difference of treatment failure between different demographic 
groups. This may be partly due to small groups. Patients of high age have a significant lower 
failure rate than the younger patients. A european observational study has found similar data, 
that probability of virological response is higher for the older patients [2].  This may be due to 
longer period of treatment or better compliance. There is also a trend that injecting drug users 
fail more often, compliance is most likely an important factor also here. An earlier study 
shows that injecting drug users experience substantially increased rates of AIDS and death up 
to 6 years after starting HAART [3]. 
Earlier studies show that identifying biological markers for later HIV treatment failure is 
difficult [4]. In our study, there is trends that a high level of beta-2 microglobulin before 
treatment may be used as a marker of later treatment failure for some patient groups. This 
marker, which is increased in serum during immune activation, has been widely recognised as 
a marker for HIV infection and progressive disease since the 1980s [5,6,7]. A study from 
Edinburgh indicate that for drug users changes in beta2 microglobulin levels may reflect 
differences in drug-injecting behavior and are not influenced by HIV status or progression 
alone [8]. 
Young age seems to be an important predictor of later treatment failure, especially for MSM. 
We have no clear explanation for this, but compliance is possibly a factor to be considered. 
For women, a high HIV-RNA count prior to treatment and a long time of HIV diagnosis is 
predictive of failure, which is not surprising.  
Virological failure seems to be associated with an unfortunate activation of the immune 
system, with high CD8, low CD4/CD8 ratio and high beta-2 microglobulin values. This 
activation occurs despite low viral counts.  
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Time of treatment seems to be of little importance for virological failure for our HIV 
population as a whole. Earlier studies describe treatment exhaustion in HAART as a “danger 
to a substantial proportion of patients” [9]. We have found length of HIV diagnosis to be a 
significant prognostic factor for treatment failure, but time of treatment is not prognostic, 
indicating that for our population, time prior to treatment is more relevant than long treatment 
with treatment exhaustion.  
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